Spectrum Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
SPPI Spectrum Pharmaceuticals Inc
FDBC Fidelity D&D Bancorp Inc
$BUKCHET Bloomberg Coffee Subindex Euro
BMY Bristol-Myers Squibb Co
MLGO MicroAlgo Inc
FRST Primis Financial Corp
VII 7GC & Holdings Co Inc
PEBO Peoples Bancorp Inc
BIOAF Bioasis Technologies Inc
NRGOF Newrange Gold Corp

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. The Company's pipeline products include Eflapegrastim and Poziotinib. The Eflapegrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib is a, pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. The Eflapegrastim employs a LAPSCOVERY technology to enhance the duration of therapeutic effects and reduce the frequency of administration.

Closing Price
Day's Change
0.0098 (1.21%)
B/A Size
Day's High
Day's Low

10-day average volume:

China sees violent protests against COVID restrictions, and U.S. cases have been rising

1:12 pm ET November 8, 2022 (MarketWatch)

By Tomi Kilgore

Daily average for COVID-related deaths falls to 5-month low, but 33 U.S. states see cases rise from 2 weeks ago

Protests in northeastern China against the government's zero-COVID policy became violent, as seven people were arrested after a clash between residents and police enforcing quarantine restrictions, the Associated Press reported.

The violence comes after China reported 2,230 new cases in the southern manufacturing and technology hub of Guangzhou, and at a time when an increasing number of reports say the government is considering steps to ease the zero-COVID policy.

It wasn't clear who was arrested after the clash with authorities, the AP reported, but news of the arrests appeared on social media early Tuesday before being erased by government censors before noon.

In the U.S., the seven-day average of new cases totaled 39,711 on Monday, according to a New York Times tracker, which was down from 39,967 on Sunday, and down from a one-month high of 40,163 on Friday. But the daily average has increased 6% from two weeks ago, as 33 states and Washington, D.C., have seen cases rise over the same time. Stay up to date with MarketWatch's daily Coronavirus Daily column.

The states seeing the biggest increases were Nevada at 96%, Tennessee at 69% and Louisiana at 68%, the New York Times data show.

The daily average for hospitalizations was 27,412 on Monday, down from 27,481 on Sunday but up 2% from two weeks ago.

On the bright side, the daily average for COVID-related deaths fell to a five-month low of 300 on Monday, down from 318 on Sunday and 15% below the average seen two weeks ago.

Meanwhile, the number of Americans who have completed the original primary series of vaccinations has barely budged from 68.5% of the total population, while the those eligible who have received updated (bivalent) booster shots sits at 8.4% of the total population, according to the latest Centers for Disease Control and Prevention data.

Novavax Inc. (NVAX) said Tuesday that a Phase 3 trial of its vaccine targeting the COVID variant omicron supports its continued use as a booster.

"The data demonstrate that the BA.1 vaccine candidate neutralizing responses in those not previously exposed to COVID-19 were greater than those of the prototype vaccine (NVX-CoV2373), enabling a shift to a new variant vaccine, if necessary," the company said in a statement.

The prototype vaccine induced a broad immune response against the original coronavirus, as well as the BA.1 and BA.5 variant strains.

On a global basis, the total number of COVID cases has increased to 633.16 million, while deaths have reached 6,602,183, according to data provided by Johns Hopkins University. The U.S. has seen a total of 97.78 million cases and 1,072,749 deaths.

-Tomi Kilgore


(END) Dow Jones Newswires

November 08, 2022 13:12 ET (18:12 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.